Lawmakers: Increase Competition In The Prescription Drug Market – Don’t Constrain It. S. 127, the “Pharmacy Benefit Manager Transparency Act of 2023” fundamentally misconstrues the role of pharmacy benefit companies, who are working every day to secure savings, enable better
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is announcing the additions of Angela Banks as Vice President, Policy; Jonathan Buxton as Director, State Affairs; and Peter Fjelstad as Director, State Regulatory and Legal Affairs, as well as new
New Research Paper Demonstrates Declining Biosimilars Prices and Increasing Health Plan Coverage (Washington, D.C.) — Pharmacy benefit managers, PBMs, support the proliferation and use of biosimilars. A robust biosimilar market will increase competition for biologic drugs and provide added choice
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play a critical role in helping to lower prescription drug costs for Americans. As biosimilar competition
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is announcing the addition of Michael Power as Senior Director, State Affairs and new roles for Tim Dube, Melodie Shrader, Heather Cascone, and Randy Kane. Michael Power joins PCMA with a long list
This week, the U.S. Senate Health, Education, Labor & Pensions (HELP) Committee considers legislation that would lower choice in the market by creating a one-size-fits all pharmacy benefit contracting model for health plans and employers. As Congress considers mandating contracting
(Washington, D.C.) — As drugstore lobbyists descend on Albany today, it is important to highlight how pharmacy benefit managers (PBMs) advocate for consumers and health plan sponsors in the fight to keep prescription drugs accessible and affordable. It is equally
Pharmacy Benefit Companies Innovate to Provide Choice for Clients, Lower Costs for Patients Even as Congress considers more government intervention and “drug pricing” legislation that ironically may prove only to increase prescription drug costs, pharmacy benefit companies continue to evolve
Mark Merritt, chief executive of PCMA, dislikes the proposal and believes the Medicare coverage is a “sound program”
New Paper Finds Potential Cost Savings from Adalimumab Biosimilars are Significant but Competitive Market Will Take Time The Pharmaceutical Care Management Association (PCMA) agrees that biosimilars bring more competition to the prescription drug marketplace, which is critical to lowering costs
©2024 PCMA. All Rights Reserved.
